MRI Perfusion on T1 and T2 Brain Lesion(s) (METAPERF)

April 17, 2026 updated by: University Hospital, Lille

Comparison of MRI Sequences T1 and T2 * Cerebral Perfusion to Aid in the Diagnosis and Evaluation of Brain Therapeutic Response With Chemotherapy or Targeted Therapy(s) Lesion(s) in Patients Treated and Followed for a Pulmonary Neoplasia

This study therefore aims to assess current treatment recommended by scientific societies [ 6-13 ] , brain MRI with injection of contrast for the diagnosis and monitoring of brain metastases . The recommended dose of this examination gadolinium is from 0.1 to 0.3 mmol / kg [ 14 ] . Sequences infusion different from one center to the other made : some use the infusion T1, other infusion T2 * . No recommendation establishes whether it is preferable to use one or the other of these sequences.

No examination is added for the purposes of protocol. Indications for MRI and the number and timing of MRI checks under this protocol are consistent with what is done in practice . The used type of gadolinium and the injected dose will be identical for both sequences infusion . The assessment shall not in any case the contrast but the interpretation of the sequence itself. Special procedures monitoring implemented embodiment correspond to the two sequences instead of infusion (one of T1-weighted and T2 * in the other ) , in the original MRI and MRI of the first control , in order to compare their effectiveness

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Eligibility criteria:

  • Major Patients
  • Addressed MRI for initial assessment of brain metastases
  • At a suspicion of one or more brain metastases in the brain scanner routine screening
  • Follow for lung cancer histologically documented
  • In the Thoracic Oncology Service Professor Lafitte (contact: Dr Cortot)
  • To whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered
  • Be socially insured

Main Outcomes measures:

Comparing the area under the ROC curve of different parameters evaluated in T1 and T2 * perfusion during the initial assessment for the diagnosis of maximal tumor response evaluated at 1 year

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Lille, France, 59037
        • Hopital Salengro CHRU de Lille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Major Patients
  • Addressed to MRI for initial assessment of brain metastases
  • At a suspicion of one or more brain metastases in the brain scanner routine screening
  • Followed for lung cancer histologically documented in the Thoracic Oncology Service of Professor Lafitte (contact: Dr Cortot)
  • To whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered
  • Be socially insured-

Exclusion Criteria:

  • Absolute contraindication to MRI (pacemaker, implantable pacemaker, metallic foreign body intraorbital)
  • Patients minors under guardianship / curatorship
  • Patients with impaired judgment skills or unable to receive information
  • Pregnant Women
  • Patients for which lesions are not compatible with lung metastases
  • Patients with brain metastases or already known and explored MRI
  • Patients for whom treatment by surgical excision of brain metastases is considered

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MRI T1 T2 sequences
comparison of perfusion sequences T1 T2 in patients with brain metastase cancer
Other: MRI T1 T2 sequences
MRI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparing different parameters evaluated in T1 and T2 * perfusion
Time Frame: 3 years
Comparing the area under the ROC curve of different parameters evaluated in T1 and T2 * perfusion during the initial assessment for the diagnosis of maximal tumor
3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation tumor response
Time Frame: 1 year
Comparison of the area under the ROC curve of the change in the first control of the various parameters measured in T1 and T2 * infusion, for the diagnosis of maximum tumor response evaluated at 1 year
1 year
Radiological progression-free survival
Time Frame: 1 year
Comparison of the ability of the two sequences to predict infusion:
1 year
Survival without neurological signs
Time Frame: 1 year
Comparison of the ability of the two sequences to predict infusion:
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Lille

Investigators

  • Study Director: Xavier LECLERC, Professor, CHRU of Lille

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2013

Primary Completion (Actual)

May 1, 2015

Study Completion (Actual)

November 1, 2015

Study Registration Dates

First Submitted

June 5, 2014

First Submitted That Met QC Criteria

September 24, 2014

First Posted (Estimated)

September 26, 2014

Study Record Updates

Last Update Posted (Actual)

April 22, 2026

Last Update Submitted That Met QC Criteria

April 17, 2026

Last Verified

November 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2012_27
  • 2012-A01644-39 (Other Identifier: ID RCB number, ANSM)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Carcinoma Metastatic to the Brain

Clinical Trials on MRI T1 T2 sequences

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe